首页> 外文OA文献 >Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment.

【2h】

Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment.

机译：通过FISH进行ALK重排测试的微观成本分析，以确定在NSCLC中进行克唑替尼治疗的资格：对测试和治疗的成本效益的影响。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

International audience

机译：国际观众

著录项

作者
Parker, David; Belaud-Rotureau, Marc-Antoine;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种 en
中图分类

相似文献

外文文献
中文文献
专利

1. Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment [J] . David Parker, Marc-Antoine Belaud-Rotureau Clinical Medicine Insights: Oncology . 2014,第8期

机译：通过FISH进行ALK重排测试的微观成本分析，以确定NSCLC中克唑替尼治疗的资格：对测试和治疗的成本效益的影响
2. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. [J] . Sandjar Djalalov, Jaclyn Beca, Jeffrey S Hoch, Journal of Clinical Oncology . 2014,第10期

机译：EML4-ALK融合测试和克唑替尼一线治疗晚期ALK阳性非小细胞肺癌患者的成本效益。
3. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. [J] . Sandjar Djalalov, Jaclyn Beca, Jeffrey S Hoch, Journal of Clinical Oncology . 2014,第10期

机译：EML4-ALK融合试验和一线沿屈杆肝癌治疗患者的成本效益，对先进的ALK阳性非小细胞肺癌的治疗。
4. Portable Floating Fish Collector: development, deployment, and testing of a cost-effective means to collect and transfer juvenile ESA fish in reservoirs to further downstream migrant research. [C] . Sean Askelson, David Griffith Hydrovision International Conference and Exhibition . 2016

机译：便携式浮式鱼收集器：开发，部署和测试成本效益的手段，用于在水库中收集和转移少年欧洲欧洲欧洲欧洲核心综合组织鱼类以进一步下游移民研究。
5. Analysis of HER2 testing in breast cancer: Disparities, cost-effectiveness, and patterns of care. [D] . Ashok, Mahima. 2009

机译：乳腺癌HER2检测分析：差异，成本效益和护理方式。
6. Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment [O] . David Parker, Marc-Antoine Belaud-Rotureau 2014

机译：通过FISH进行ALK重排测试的微观成本分析以确定NSCLC中克唑替尼治疗的资格：对测试和治疗的成本效益的影响
7. Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment. [O] . Parker, David, Belaud-Rotureau, Marc-Antoine 2013

机译：通过FISH进行ALK重排测试的微成本分析，以确定NSCLC中克唑替尼治疗的资格：测试和治疗成本效益的含义。
8. The Implications of Cost-Effectiveness Analysis of Medical Technology. Background Paper No. 2: Case Studies of Medical Technologies. Case Study No. 6: The Cost Effectiveness of Bone Marrow Transplant Therapy and Its Policy Implications [R] . Schweitzer, S. O. , Scalzi, C. C. 1981

机译：医疗技术成本效益分析的启示。背景文件第2号：医疗技术案例研究。第6号案例研究：骨髓移植治疗的成本效益及其政策含义

Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment.

摘要

著录项

相似文献

相关主题

期刊订阅